

Survival of the Fittest Group: Factorial Analyses of Treatment Effects under Independent Right-Censoring

Dennis Dobler^{1*} and Markus Pauly²

¹Department of Mathematics, Vrije Universiteit Amsterdam, Netherlands.

²Institute of Statistics, Ulm University, Germany.

November 25, 2021

Abstract

This paper introduces new effect parameters for factorial survival designs with possibly right-censored time-to-event data. In the special case of a two-sample design it coincides with the concordance or Wilcoxon parameter in survival analysis. More generally, the new parameters describe treatment or interaction effects and we develop estimates and tests to infer their presence. We rigorously study the asymptotic properties by means of empirical process techniques and additionally suggest wild bootstrapping for a consistent and distribution-free application of the inference procedures. The small sample performance is discussed based on simulation results. The practical usefulness of the developed methodology is exemplified on a data example about patients with colon cancer by conducting one- and two-factorial analyses.

Keywords: Empirical process, Factorial designs, Kaplan-Meier estimator, Quadratic forms, Wild bootstrap

* e-mail: d.dobler@vu.nl

1 Motivation and Introduction

Many biomedical and clinical trials are planned as factorial designs. Here, not only the (main) effects of separate factors but also interaction effects that are related to possibly complex factor combinations are of importance. Such interaction effects may even alter the interpretation of main effects leading to the established comment by Lubsen and Pocock (1994) that ‘*it is desirable for reports of factorial trials to include estimates of the interaction between the treatments*’.

On the other hand, *nonparametric* estimation and the inference of adequate effects in such designs can be rather involved. In particular, most existing inference procedures have focused on testing hypotheses formulated in terms of distribution functions (Brunner et al., 1997; Brunner and Puri, 2001; Gao and Alvo, 2005, 2008; Gao et al., 2008; Akritas, 2011; Dutta and Datta, 2016; Friedrich et al., 2017; Umlauf et al., 2017a) which cannot be inverted to obtain confidence intervals or regions for meaningful effects. Only recently, nonparametric methods for inferring adequate effects in general factorial designs with independent and dependent observations have been established (Konietzschke et al., 2016; Brunner et al., 2017; Umlauf et al., 2017b; Dobler et al., 2018). These procedures are, however, only developed for completely observed data and not applicable for partially observed time-to-event data. Since many clinical studies are concerned with survival outcomes, adequate statistical inference methods for complex factorial time-to-event designs are of particular interest.

To detect main effects, weighted logrank tests or their extensions may be applied in case of two or multiple samples (Mantel, 1966; Andersen et al., 1993; Ehm et al., 1995; Liu and Dahlberg, 1995; Janssen and Neuhaus, 1997; Bathke et al., 2009; Yang and Prentice, 2010; Fleming and Harrington, 2011; Brendel et al., 2014). However, these procedures only infer conclusions in terms of cumulative hazard functions and cannot be applied to obtain concrete *effect parameters* with informative confidence intervals nor tests for the presence of interactions. In practice, interaction effects are usually modeled with the help of Cox-, Aalen- or even Cox-Aalen regression models (Cox, 1972; Scheike and Zhang, 2002, 2003) with factors as covariates and incorporated interaction terms. However, although very flexible, these models are usually more driven towards hazards modeling by continuous covariates while the incorporation of several factor variables (e.g., via multiple dummy variables per factor) can become cumbersome; especially when interactions are incorporated, see also Green et al. (2002) and Green (2012) for the uncensored case.

The above problems directly motivate a nonparametric approach for estimating and inferring main and interaction effects in factorial designs with censored observations. So far, the only existing methods in this context are given by the nonparametric survival procedures of Akritas and Brunner (1997) and Akritas (2011). They are based on a purely nonparametric model that does not require any multiplicative or additive structure of the hazards and can even be applied for arbitrary, possibly non-continuous survival distributions (i.e., it can be readily used for survival times rounded to days, weeks or months). Moreover, it leads to tests for main and interaction effects in case of independent right-censored data. However, these tests suffer from several drawbacks: the procedure is based on a rather strong assumption on the underlying censorship distribution which is often hard to verify in practical situations. In addition, null hypotheses are only formulated in terms of distribution functions. As a result, there is no direct quantification and estimation of main and interaction effects in terms of confidence intervals as, e.g., required by regulatory authorities (ICH E9 Guideline, 1998, p. 25).

This is to be changed in the current paper. We develop and rigorously analyze nonparametric inference procedures, i.e. tests and confidence intervals, for meaningful effect sizes in factorial survival designs, where data may be subject to random right-censoring.

Similar to the adaption of the Brunner and Munzel (2000) test to the two-sample survival set-up by Dobler and Pauly (2017), we consider the recently proposed unweighted nonparametric effects of Brunner et al. (2017) and extend their ansatz to a general survival setting. In the special case of proportional hazards, these effects have a direct relationship to hazard ratios in two-sample settings (Brückner and Brannath, 2017) while they remain meaningful in case of non-proportional hazards. This fact makes the effect sizes even more appealing for practical purposes.

The paper is organized as follows. The statistical model and important results on the basic estimators are presented in Section 2. The resulting test statistic for the null hypotheses of interest is stated and mathematically analyzed in Section 3. Since the asymptotic distribution of the test statistic depends on unknown parameters, we propose a distribution-free multiplier resampling approach in Section 4 and prove its consistency. In Section 5 it is supplemented by a simulation study to assess the finite sample properties of the proposed procedure. They are then exemplified on a colon cancer study in Section 6, where in the original study (Moertel et al., 1990) the analysis was made in terms of Cox models. Finally, the paper closes with concluding comments in Section 7. All proofs are deferred to the technical Appendix.

2 The set-up

To establish the general model, we consider sequences of mutually independent random variables

$$T_{ik} \stackrel{\text{ind}}{\sim} S_i \quad \text{and} \quad C_{ik} \stackrel{\text{ind}}{\sim} G_i \quad (i = 1, \dots, d, k = 1, \dots, n_i), \quad (1)$$

where T_{ik} denotes the actual survival time of subject k in group i and C_{ik} the corresponding censoring variable. Moreover, to even allow for ties or survival times rounded to weeks or months, the survival functions S_i and G_i , $i = 1, \dots, d$,

defined on $(0, \infty)$ may be *possibly discontinuous*. That is, the corresponding hazard rates may, but need not exist. The actually observable data consist of the right-censored survival times $X_{ik} = T_{ik} \wedge C_{ik}$ and the uncensoring indicators $\delta_{ik} = 1\{T_{ik} \leq C_{ik}\}$, $i = 1, \dots, d$, $k = 1, \dots, n_i$. In this set-up, a factorial structure can be incorporated by splitting up indices, see Section 5 for details.

In the special case of $d = 2$ groups with continuous survival times Efron (1967) introduced an estimator for the *concordance probability*

$$w = P(T_{11} > T_{21}) = - \int S_1 dS_2$$

that a randomly chosen subject from the first group survives longer than someone from the second group. If all subjects are completely observable, this effect size w reduces to the well-known Mann-Whitney effect underlying the Brunner and Munzel (2000) test. Inference procedures for w and related quantities in survival set-ups (such as the concordance parameter or the average hazard ratio) have, e.g. been developed by Brückner and Brannath (2017); Dobler and Pauly (2017). However, an extension of the definition of w to the more general design (1), allowing for an arbitrary factorial structure, is not straightforward. In particular, for the case of completely observed data, Brunner et al. (2017) and Brunner et al. (2018) point out several pitfalls that may lead to paradoxical results when working with a ‘wrong’ extension of w . Adopting their solution to the present situation, we introduce an additional ‘benchmark’ survival time Z , independent of the above, with averaged survival function $Z \sim \bar{S} = \frac{1}{d} \sum_{i=1}^d S_i$. This is used to extend w to

$$\tilde{p}_i = P(T_{i1} > Z) + \frac{1}{2}P(T_{i1} = Z) = - \int S_i^\pm d\bar{S},$$

where the superscript \pm denotes the average of a right-continuous function and its left-continuous version. The use of such normalized survival functions adequately handles discrete components of the survival distribution, i.e. ties in the data are explicitly allowed.

The choice of the effect parameter \tilde{p}_i is motivated by recent findings on nonparametric analyses of factorial designs with complete observations in Brunner et al. (2017, 2018). They stress that other choices, e.g. pairwise-comparisons of all concordance probabilities w or comparisons with the weighted survival function $\sum_{i=1}^d \frac{n_i}{N} S_i$ instead of \bar{S} , may easily result in paradoxical outcomes. This is no issue for the effects \tilde{p}_i which are sample size independent. For later calculations, we emphasize that the effect parameters are balanced in the mean. In particular, we have

$$\frac{1}{d} \sum_{i=1}^d \tilde{p}_i = - \int \bar{S}^\pm d\bar{S} = \frac{1}{2} \quad \text{and} \quad \tilde{p}_i = - \sum_{\substack{j=1 \\ j \neq i}}^d \int S_i^\pm dS_j + \frac{1}{2d}.$$

From a practical point of view, estimation of the \tilde{p}_i ’s would need ‘arbitrarily’ large survival times since the integral is defined on $(0, \infty)$. However, every study ends at a certain point in time. For practical applicability, we therefore assume that the censoring times are bounded and we have to modify the \tilde{p}_i ’s accordingly: denote by $\tau > 0$ the largest possible censoring time. In comparisons of survival times, which belong to different groups and which exceed τ , no group shall be favored. In other words, the remaining mass has to be split up equally among the groups. Technically, this is realized by setting the remaining mass of the survival functions to zero: $S_i(\tau) = 0$. Redefining S_i and \bar{S} from now on as the survival functions of $\min(T_{i1}, \tau)$ and $\min(Z, \tau)$, respectively, this translates into the *nonparametric concordance effects*

$$p_i = P(\min(T_{i1}, \tau) > \min(Z, \tau)) + \frac{1}{2}P(\min(T_{i1}, \tau) = \min(Z, \tau)) = - \int S_i^\pm d\bar{S}. \quad (2)$$

Obviously, all of the above-discussed positive properties of the effects parameter \tilde{p}_i also transfer to the nonparametric concordance effects p_i : it is a meaningful effect measure for ordinal and metric data, sample size independent, and allows for a suitable treatment of ties.

We aggregate all effects into the vector $\mathbf{p} = (p_1, \dots, p_d)'$ and borrow a trick from Konietzschke et al. and Brunner et al. (2017) to express them as

$$\mathbf{p} = \left(\mathbf{I}_d \otimes \frac{1}{d} \mathbf{1}'_d \right) \cdot (\mathbf{w}'_1, \dots, \mathbf{w}'_d)' =: \mathbf{E}_d \cdot \mathbf{w}. \quad (3)$$

Here, $\mathbf{w}_i = (w_{1i}, \dots, w_{di})' = - \int S_i^\pm d\mathbf{S}$ is the \mathbb{R}^d -vector of effects for direct comparisons of group i with respect to all groups $j = 1, \dots, d$, and $\mathbf{S} = (S_1, \dots, S_d)'$ is the aggregation of all survival functions. Moreover, \mathbf{I}_d denotes the identity matrix in \mathbb{R}^d , $\mathbf{1}_d$ the d -dimensional vector of 1’s and the symbol \otimes denotes the Kronecker product. In this way the i th entry of \mathbf{w}_i is $w_{ii} = \frac{1}{2}$ which makes sense because equal groups should be valued equally high. Anyhow, Equation (3) shows that the problem of estimating \mathbf{p} reduces to the estimation of the pair-wise effects w_{ji} . But this can be achieved by substituting each involved survival function S_i by its Kaplan-Meier estimator \hat{S}_i , $i = 1, \dots, d$ (Kaplan and Meier, 1958). Proceeding in this way we denote by $\hat{\mathbf{w}}$ and $\hat{\mathbf{w}}_i$ these estimated counterparts of \mathbf{w} and \mathbf{w}_i . Let $N = \sum_{i=1}^d n_i$ be the total sample size. Below we establish the asymptotic normality of $\sqrt{N}(\hat{\mathbf{w}} - \mathbf{w})$ under the following framework:

$$N^{-1} \mathbf{n} := \left(\frac{n_1}{N}, \dots, \frac{n_d}{N} \right)' \rightarrow \boldsymbol{\lambda} := (\lambda_1, \dots, \lambda_d)' \in (0, 1)^d \quad (4)$$

as $\min \mathbf{n} \rightarrow \infty$. To give a detailed description of the resulting asymptotic covariance structure, however, we first have to introduce some additional notation: Let $D[0, \tau]$ be the space of all càdlàg-functions on $[0, \tau]$, equipped with the Skorokhod metric, and $BV[0, \tau] \subset D[0, \tau]$ its subspace of càdlàg-functions with bounded variation. For the subsequent arguments it is essential that we can represent $\mathbf{w} = \phi \circ \mathbf{S}$ as a functional of \mathbf{S} . In particular, the functional

$$\phi : (BV[0, \tau])^d \rightarrow \mathbb{R}^d, \quad (f_1, \dots, f_d)' \mapsto \left(- \int f_i^\pm df_j \right)_{i,j=1}^d,$$

with inner index j , is Hadamard-differentiable at \mathbf{S} ; see the proof of Lemma 1 below for details. We denote its Hadamard-derivative at \mathbf{S} by $d\phi_{\mathbf{S}}$, which is a continuous linear functional. For technical reasons, we assume throughout that $P(T_{i1} > \tau) > 0$ for all groups $i = 1, \dots, d$. We may now state the first preliminary but essential convergence result.

Lemma 1. *Under the asymptotic regime (4) we have*

$$\sqrt{N}(\hat{\mathbf{w}} - \mathbf{w}) \xrightarrow{d} \mathbf{W},$$

where \mathbf{W} has a centered multivariate normal distribution on \mathbb{R}^d .

In particular, we can write $\mathbf{W} = d\phi_{\mathbf{S}} \cdot \text{diag}(\boldsymbol{\lambda})^{-1/2} \mathbf{U}$, where \mathbf{U} consists of independent, zero-mean Gaussian processes U_1, \dots, U_d with covariance functions

$$\Gamma_i(r, s) = S_i(r)S_i(s) \int_0^{r \wedge s} \frac{d\Lambda_i}{S_i - G_{i-}(1 - \Delta\Lambda_i)}, \quad i = 1, \dots, d,$$

where Λ_i denotes the cumulative hazard function corresponding to $S_i = \prod(1 - d\Lambda_i)$, $i = 1, \dots, d$; the symbol \prod denotes the product integral (Gill and Johansen, 1990). Here, a minus sign in a subscript indicates the left-continuous version of a function and $\Delta\Lambda = \Lambda - \Lambda_-$ is the jump size function of Λ . Note that the covariance matrix of \mathbf{W} is singular; in particular, $(d\phi_{\mathbf{S}} \cdot \text{diag}(\boldsymbol{\lambda})^{-1/2} \mathbf{U})_{i,i} = 0$ for all $i = 1, \dots, d$. The other entries ($i \neq j$) are distributed as follows:

$$(d\phi_{\mathbf{S}} \cdot \text{diag}(\boldsymbol{\lambda})^{-1/2} \mathbf{U})_{i,j} = \frac{1}{\sqrt{\lambda_i}} \int U_i^\pm dS_j - \frac{1}{\sqrt{\lambda_j}} \int U_j^\pm dS_i \sim N\left(0, \frac{1}{\lambda_i} \int \int \Gamma_i^{\pm\pm} dS_j dS_j + \frac{1}{\lambda_j} \int \int \Gamma_j^{\pm\pm} dS_i dS_i\right).$$

Here, the double appearance of \pm signs means the average of all four combinations of left- and right- continuous versions in both arguments of a two-parameter function.

Let us now turn to the estimation of the nonparametric concordance effects \mathbf{p} . A matrix multiplication of $\hat{\mathbf{w}}$ with \mathbf{E}_d from the left is basically the same as taking the mean with respect to the inner index j . This immediately brings us to the first main result:

Theorem 1. *Under the asymptotic regime (4) we have*

$$\sqrt{N}(\hat{\mathbf{p}} - \mathbf{p}) := \sqrt{N}\mathbf{E}_d(\hat{\mathbf{w}} - \mathbf{w}) \xrightarrow{d} \mathbf{E}_d\mathbf{W} = \left(\frac{1}{d} \sum_{i=1}^d \frac{1}{\sqrt{\lambda_i}} \int U_i^\pm dS_j - \frac{1}{\sqrt{\lambda_j}} \int U_j^\pm d\bar{S} \right)_{j=1}^d,$$

where $\mathbf{E}_d\mathbf{W}$ has the variance-covariance matrix \mathbf{V} with the following entries:

$$V_{ii} = \frac{1}{\lambda_i} \int \int \Gamma_i^{\pm\pm} d\bar{S} d\left(\bar{S} - \frac{2}{d}S_i\right) + \frac{1}{d^2} \sum_{j=1}^d \frac{1}{\lambda_j} \int \int \Gamma_j^{\pm\pm} dS_i dS_i$$

in the i th diagonal entry, $i = 1, \dots, d$, and

$$V_{ij} = \frac{1}{d^2} \sum_{j=1}^d \frac{1}{\lambda_j} \int \int \Gamma_j^{\pm\pm} dS_i dS_j - \frac{1}{d} \frac{1}{\lambda_i} \int \int \Gamma_i^{\pm\pm} d\bar{S} dS_j - \frac{1}{d} \frac{1}{\lambda_j} \int \int \Gamma_j^{\pm\pm} d\bar{S} dS_i$$

in the off-diagonal entries (i, j) , $i \neq j$.

A more compact form of the matrix \mathbf{V} is given in Appendix B.

3 Choice of Test Statistic

In order to develop hypothesis tests based on the estimator $\hat{\mathbf{p}}$, we next need to find a consistent estimator $\hat{\mathbf{V}}_N$ for \mathbf{V} . A natural choice is to plug in estimators for all unknown quantities that are involved in \mathbf{V} . In particular, we use the Kaplan-Meier estimators for all survival functions and $\hat{\Gamma}_i(s, t) = \hat{S}_i(s)\hat{S}_i(t)n_i \int_0^{s \wedge t} [Y_i(1 - \Delta\hat{\Lambda}_i)]^{-1} d\hat{\Lambda}_i$ for each covariance function Γ_i , where Y_i is the number at risk process and $\hat{\Lambda}_i$ is the Nelson-Aalen estimator for the cumulative hazard matrix in group i . Note that if $\Delta\hat{\Lambda}_i(u) = 1$, we also have $\hat{S}_i(u) = 0$ in which case we let $\hat{\Gamma}_i(s, t) = 0$ if $s \geq u$ or $t \geq u$. We denote the resulting covariance matrix estimator by $\hat{\mathbf{V}}_N$.

Lemma 2. *Under the asymptotic regime (4) we have the consistency $\widehat{\mathbf{V}}_N \xrightarrow{P} \mathbf{V}$.*

All of the developed convergence results are now utilized to find the most natural test statistic. First note that the asymptotic covariance matrix \mathbf{V} is singular since $\mathbf{1}'_d \sqrt{N}(\widehat{\mathbf{p}} - \mathbf{p}) \equiv 0$, whence $r(\mathbf{V}) \leq d - 1$ follows. Furthermore, it is not at all obvious whether the ranks of the Moore-Penrose inverse $r((\mathbf{C}\widehat{\mathbf{V}}_N\mathbf{C}')^+)$ converge in probability to the rank $r((\mathbf{C}\mathbf{V}\mathbf{C}')^+)$ for a compatible contrast matrix \mathbf{C} . Hence, the Wald-type statistic $N\widehat{\mathbf{p}}'\mathbf{C}'(\mathbf{C}\widehat{\mathbf{V}}_N\mathbf{C}')^+\widehat{\mathbf{C}}\widehat{\mathbf{p}}$ is not suitable for testing $H_0^p(\mathbf{C}) : \mathbf{C}\mathbf{p} = \mathbf{0}$: Its asymptotic behaviour is unclear and, hence, there is no reasonable choice of critical values.

Instead, we utilize a statistic that does not rely on the uncertain convergence of ranks of generalized inverses. This leads us to the survival version of the so-called ANOVA-rank-type statistic

$$F_N(\mathbf{T}) = \frac{N}{\text{tr}(\mathbf{T}\widehat{\mathbf{V}}_N)} \widehat{\mathbf{p}}'\mathbf{T}\widehat{\mathbf{p}}, \quad (5)$$

where $\mathbf{T} = \mathbf{C}'(\mathbf{C}\mathbf{C}')^+\mathbf{C}$ is the unique projection matrix onto the column space of \mathbf{C} . Below we analyze both, its asymptotic behaviour under null hypotheses of the form $H_0^p(\mathbf{C}) : \mathbf{C}\mathbf{p} = \mathbf{0}$ and under the corresponding alternative hypotheses $H_a^p(\mathbf{C}) : \mathbf{C}\mathbf{p} \neq \mathbf{0}$.

Theorem 2. *Assume the asymptotic regime (4) and that $\text{tr}(\mathbf{T}\mathbf{V}) > 0$.*

a) *Under $H_0^p(\mathbf{C})$ and as $N \rightarrow \infty$, we have $F_N(\mathbf{T}) \xrightarrow{d} \chi = \mathbf{W}'\mathbf{E}'_d\mathbf{T}\mathbf{E}_d\mathbf{W}/\text{tr}(\mathbf{T}\mathbf{V})$ which is non-degenerate and non-negative with $E(\chi) = 1$.*

b) *Under $H_a^p(\mathbf{C})$ and as $N \rightarrow \infty$, we have $F_N(\mathbf{T}) \xrightarrow{P} \infty$.*

As the distribution of χ depends on unknown quantities (cf. Theorem 1) the test statistic $F_N(\mathbf{T})$ in (5) is no asymptotic pivot. To nevertheless obtain proper critical values which lead to asymptotically exact inference procedures we next propose and study a resampling approach.

4 Inference via Multiplier Bootstrap

In this section, we apply suitably tailored multiplier bootstrap techniques in order to approximate the small sample distribution of $F_N(\mathbf{T})$. To this end, we consider the situation under $H_0^p(\mathbf{C})$ in which case we may expand

$$F_N(\mathbf{T}) = \frac{N}{\text{tr}(\mathbf{T}\widehat{\mathbf{V}}_N)} (\widehat{\mathbf{p}} - \mathbf{p})'\mathbf{T}(\widehat{\mathbf{p}} - \mathbf{p}) = \frac{N}{\text{tr}(\mathbf{T}\widehat{\mathbf{V}}_N)} (d\phi_{\mathbf{S}} \cdot (\widehat{\mathbf{S}} - \mathbf{S}))'\mathbf{E}'_d\mathbf{T}\mathbf{E}_d(d\phi_{\mathbf{S}} \cdot (\widehat{\mathbf{S}} - \mathbf{S})) + o_p(1),$$

where $\widehat{\mathbf{S}}$ is the vectorial aggregation of all Kaplan-Meier estimators $\widehat{S}_1, \dots, \widehat{S}_d$. First, we replace the martingale residuals, that are attached to the Kaplan-Meier estimators, with independent centered random variables which have approximately the same variance. In particular, we replace $\sqrt{N}(\widehat{S}_i - S_i)$ with

$$\widehat{S}(t) \cdot \sqrt{N} \sum_{k=1}^{n_i} G_{ik} \int_0^t [(Y_i(u) - \Delta N_i(u))Y_i(u)]^{-1/2} dN_{ik}(u);$$

cf. Dobler (2017) for a similar wild bootstrap Greenwood-type correction for tied survival data. Here we utilized the usual counting process notation (Andersen et al., 1993): N_{ik} indicates whether the event of interest already took place for individual k in group i . The *wild bootstrap* multipliers $G_{ik}, i = 1, \dots, n_i, i = 1, \dots, d$, are i.i.d. with zero mean and unit variance and also independent of the data. In Bluhmki et al. (2018a,b) a similar multiplier resampling approach is applied to Nelson-Aalen and Aalen-Johansen estimators in one- and two-sample problems.

In a next step toward the construction of a wild bootstrap statistic, we replace $d\phi_{\mathbf{S}}$ with $d\phi_{\widehat{\mathbf{S}}}$. Let us denote the thus obtained wild bootstrap version of $\sqrt{N}d\phi_{\mathbf{S}} \cdot (\widehat{\mathbf{S}} - \mathbf{S})$ by \mathbf{W}_N^* . Conditionally on the data, this d^2 -variate random vector is for large N approximately normally distributed and its limit distribution coincides with that of \mathbf{W} ; see the proof of Theorem 3 below for details.

Finally, a wild bootstrap version $F_N^*(\mathbf{T})$ of $F_N(\mathbf{T})$ requires that we also use a consistent wild bootstrap-type estimator $\text{tr}(\mathbf{T}\widehat{\mathbf{V}}_N^*)$ of $\text{tr}(\mathbf{T}\widehat{\mathbf{V}}_N)$. It is found by replacing the estimators $\widehat{\Gamma}_i$ with

$$\Gamma_i^*(s, t) = \widehat{S}_i(s)\widehat{S}_i(t) n_i \sum_{k=1}^{n_i} G_{ik}^2 \int_0^{s \wedge t} \frac{dN_{ik}}{(Y_i - \Delta N_i)Y_i}.$$

Its conditional consistency was argued in Dobler (2017) and a sufficient condition for this is $E(G_{11}^4) < \infty$. These wild bootstrap-type variance estimators also have the nice interpretation of optional variation processes of the wild bootstrapped Kaplan-Meier estimators (Dobler, 2017). Hence, the resulting wild bootstrap version of $F_N(\mathbf{C})$ is

$$F_N^*(\mathbf{T}) = \frac{1}{\text{tr}(\mathbf{T}\widehat{\mathbf{V}}_N^*)} \mathbf{W}_N^{*\prime}\mathbf{E}'_d\mathbf{T}\mathbf{E}_d\mathbf{W}_N^*.$$

The following conditional central limit theorem ensures the consistency of this resampling approach.

Theorem 3. Assume $E(G_{11}^4) < \infty$ and that the conditions of Theorem 2 hold. Conditionally on $(X_{ik}, \delta_{ik}), i = 1, \dots, d, k = 1, \dots, n_i$, we have for all underlying values of \mathbf{p}

$$F_N(\mathbf{T})^* \xrightarrow{d} \chi = \mathbf{W}'\mathbf{E}'_d\mathbf{T}\mathbf{E}_d\mathbf{W}/\text{tr}(\mathbf{T}\mathbf{V})$$

in probability as $N \rightarrow \infty$.

We would like to stress that the limit distribution coincides with that of $F_N(\mathbf{T})$ under $H_0^p(\mathbf{C})$. For the wild bootstrap version $F_N(\mathbf{T})^*$, however, the convergence result holds under both, the null and the alternative hypothesis, i.e. its conditional distribution always approximates the correct null distribution of the test statistic.

We conclude the theoretical part of this article with a presentation of deduced inference procedures for the effect sizes \mathbf{p} . To this end, let $c_{N,\alpha}^*$ denote the $(1 - \alpha)$ -quantile, $\alpha \in (0, 1)$, of the conditional distribution of $F_N^*(\mathbf{T})$ given the data. In practice, this quantile is approximated via simulation by repeatedly generating sets of the wild bootstrap multipliers G_{ki} .

Corollary 1. Under the assumptions of Theorem 3, the test

$$\varphi_N = 1\{F_N(\mathbf{T}) > c_{N,\alpha}^*\}$$

is asymptotically exact and consistent. That is, $E(\varphi_N) \rightarrow \alpha \cdot 1_{H_0^p(\mathbf{C})} + 1_{H_a^p(\mathbf{C})}$ as $N \rightarrow \infty$.

Now, let r be the number of columns of \mathbf{C}' and denote by $\mathbf{c}_1, \dots, \mathbf{c}_r$ its column vectors. The presentation of a simultaneous confidence region for the contrasts $\mathbf{c}'_\ell \mathbf{p}, \ell = 1, \dots, r$, in Corollary 2 below will be done in an implicit manner.

Corollary 2. Under the assumptions of Theorem 3, an asymptotically exact $(1 - \alpha)$ -confidence ellipsoid for the contrasts $\mathbf{c}'_\ell \mathbf{p}, \ell = 1, \dots, r$, is given by

$$CE = CE_{N,1-\alpha}(\mathbf{C}) = \left\{ \mathbf{v} \in \mathbb{R}^r : (\mathbf{C}\hat{\mathbf{p}} - \mathbf{v})'(\mathbf{C}\mathbf{C}')^+(\mathbf{C}\hat{\mathbf{p}} - \mathbf{v}) \leq \frac{\text{tr}(\mathbf{T}\hat{\mathbf{V}}_N)}{N} c_{N,\alpha}^* \right\}.$$

That is, $P(\mathbf{C}\mathbf{p} \in CE) \rightarrow 1 - \alpha$ as $N \rightarrow \infty$.

5 Simulations

In this section, we assess the small sample properties of the test φ_N as proposed in Corollary 1.

5.1 Behaviour under null hypotheses

We first focus on its type I error control with respect to

- various kinds of contrast matrices
- and different censoring intensities.

Design and Sample Sizes. For ease of presentation we restrict ourselves to a design with $d = 6$ groups with different sample size layouts: we considered small samples in a balanced design with $\mathbf{n}_1 = (n_1, \dots, n_6)' = (10, 10, 10, 10, 10, 10)'$ and two unbalanced designs with $\mathbf{n}_2 = (n_1, \dots, n_6)' = (10, 12, 14, 10, 12, 14)'$ and $\mathbf{n}_3 = (10, 12, 14, 14, 10, 12)'$, respectively. To obtain designs with moderate to large sample sizes we increase these vectors component-wise by the factors $K \in \{2, 3, 5, 10\}$. Moreover, depending on the question of interest, we below distinguish between a one-way layout with six independent groups and a 2×3 two-way design.

Censoring Framework. We considered exponentially distributed censoring random variables $C_{i1} \stackrel{\text{ind}}{\sim} \text{Exp}(\lambda_i)$ with the following vectors $\boldsymbol{\lambda} = (\lambda_1, \dots, \lambda_6)'$ of rate parameters: $\boldsymbol{\lambda}_1 = 0.4 \cdot \mathbf{1}$, $\boldsymbol{\lambda}_2 = 0.5 \cdot \mathbf{1}$, $\boldsymbol{\lambda}_3 = 2/3 \cdot \mathbf{1}$, $\boldsymbol{\lambda}_4 = (0.4, 0.5, 2/3, 0.4, 0.5, 2/3)'$, $\boldsymbol{\lambda}_5 = (0.4, 0.5, 2/3, 2/3, 0.5, 0.4)'$, where $\mathbf{1} \in \mathbb{R}^6$ is the vector consisting of 1s only. Thus, the first three settings correspond to equal censoring mechanisms with increased censoring rate from $\boldsymbol{\lambda}_1$ to $\boldsymbol{\lambda}_3$. The other two ($\boldsymbol{\lambda}_4$ and $\boldsymbol{\lambda}_5$) lead to unequal censoring. By considering all 75 possible combinations, many possible effects of censoring and sample size assignments are analyzed. For example, in the set-up with \mathbf{n}_2 , $K = 10$ and $\boldsymbol{\lambda}_4$, larger sample sizes are matched with a stronger censoring rate in an unbalanced design.

Contrast Matrices and Null Hypotheses. We simulated the true significance level of the tests for the null hypotheses $H_0^p(\mathbf{C}) : \mathbf{C}\mathbf{p} = \mathbf{0}$ for two designs and different contrast matrices of interest:

In case of a one-way design with $d = 6$ groups we were interested in the null hypotheses of ‘no group effect’ or ‘equality of all treatment effects’ $H_0^p(\mathbf{C}_1) : \{\mathbf{C}_1\mathbf{p} = \mathbf{0}\} = \{p_1 = \dots = p_6\}$. This may be described by considering the matrix $\mathbf{C}_1 = \mathbf{P}_6$, where here and below $\mathbf{P}_d = \mathbf{I}_d - \mathbf{J}_d/d \equiv \mathbf{I}_d - \mathbf{1}_d\mathbf{1}'_d/d$ denotes the d -dimensional centering matrix.

Next, we consider a 2×3 two-way layout with two factors A (with two levels) and B (with three levels). This is incorporated in Model (1) by setting $d = a \cdot b = 2 \cdot 3 = 6$ and splitting up the index i into two indices $i_1 = 1, 2$ (for the levels of factor A) and $i_2 = 1, 2, 3$ (for the levels of factor B). Thus, we obtain survival times $T_{i_1 i_2 k}$, $k = 1, \dots, n_{i_1 i_2}$, and corresponding nonparametric concordance effects $p_{i_1 i_2}$. More complex factorial designs can be incorporated similarly. In this 2×3 set-up we are now interested in testing the null hypotheses of

(A) ‘No main effect of factor A ’: $H_0^p(\mathbf{C}_{2,A}) : \{\mathbf{C}_{2,A}\mathbf{p} = \mathbf{0}\} = \{\bar{p}_{1\cdot} = \bar{p}_{2\cdot}\}$,

(B) ‘No main effect of factor B ’: $H_0^p(\mathbf{C}_{2,B}) : \{\mathbf{C}_{2,B}\mathbf{p} = \mathbf{0}\} = \{\bar{p}_{\cdot 1} = \bar{p}_{\cdot 2} = \bar{p}_{\cdot 3}\}$ and

(AB) ‘No $A \times B$ interaction effect’: $H_0^p(\mathbf{C}_{2,AB}) : \{\mathbf{C}_{2,AB}\mathbf{p} = \mathbf{0}\} = \{p_{i_1 i_2} - \bar{p}_{i_1\cdot} - \bar{p}_{\cdot i_2} + \bar{p}_{\cdot\cdot} = 0 \text{ for all } i_1, i_2\}$,

where $\bar{p}_{i_1\cdot}$, $\bar{p}_{\cdot i_2}$ and $\bar{p}_{\cdot\cdot}$ denote the means over the dotted indices. In particular, the corresponding contrast matrices are given by $\mathbf{C}_{2,A} = \mathbf{P}_2 \otimes \frac{1}{3}\mathbf{J}_3$, $\mathbf{C}_{2,B} = \frac{1}{2}\mathbf{J}_2 \otimes \mathbf{P}_3$, and $\mathbf{C}_{2,AB} = \mathbf{P}_2 \otimes \mathbf{P}_3$, where \otimes indicates the Kronecker product.

Survival Distributions. For ease of presentation we only considered a rather challenging scenario, where the groups follow different survival distributions. In particular, we simulated

(G1) a lognormal distribution with meanlog parameter 0 and sdlog parameter 0.2726 for the first group,

(G2) a Weibull distribution with scale parameter 1.412 and shape parameter 1.1 for the second group,

(G3) a Gamma-distribution with scale parameter 0.4 and shape parameter 2.851 for the third group and

(G4-G6) mixing distributions of all pair combinations of the first three survival functions for the last three groups.

The first three survival functions are illustrated in Figure 1. We note that preliminary simulations for more crude scenarios with identical survival distributions in all groups exhibited a much better type- I -error control of our testing procedure (results not shown). Anyhow, the parameters of the above distributions were chosen in such a way that the nonparametric concordance effects of all groups are equal, i.e. $p_i = 0.5$ for all $i = 1, \dots, 6$ (one-way) and $p_{i_1 i_2} = 0.5$ for all $i_1 = 1, 2$; $i_2 = 1, 2, 3$ (two-way), respectively. Thus, all considered null hypotheses are true. We would like to stress




Figure 1: Survival functions underlying the first three simulated sample groups.

that the case of continuously distributed survival times corresponds to an infinite-dimensional problem and is thus more difficult than the discrete case. For example, the simulation study in Dobler (2017) confirms this observation in a related problem: the convergence rate of the actual coverage probabilities of confidence bands to the nominal confidence level is much faster the more discretely distributed the survival data is. Moreover, to make the simulation scenario even more challenging, we considered the situation with infinite τ to also get an indication of the functionality of the test in this case.

Simulations. We chose as wild bootstrap multipliers centered unit Poisson variables because a formal Edgeworth expansion and two simulation studies in Dobler et al. (2017) indicate that those have theoretical and practical advantages over the common choice of standard normal multipliers. We chose the nominal level $\alpha = 5\%$ and conducted each test 10,000 times for $K = 1, 2, 3$ and 5,000 times for $K = 5, 10$ because of the massively increasing computational complexity for large samples. Each test was based on critical values that were found using 1,999 wild bootstrap iterations. All simulations were conducted with the help of the R computing environment (R Development Core Team, 2010–2015).

Results. The true type- I -error results for the four different null hypotheses are shown in Table 1 (left panel: one-way for $H_0^p(\mathbf{C}_1)$ and right panel: two-way for $H_0^p(\mathbf{C}_{2,A})$) and Table 2 (two-way for $H_0^p(\mathbf{C}_{2,B})$ in the left and $H_0^p(\mathbf{C}_{2,AB})$ in the right panel). It is apparent that all simulated levels are elevated for the smallest sample sizes ($K = 1$), especially for the one-way test: here almost all type I error probabilities are between 13.0% and 17.7%. For the two-way tests, these probabilities are mainly between 8.1% and 11.7% in this case ($K = 1$). On the one hand, this is due to the relatively strong censoring rates: for $\lambda = 0.4$, the censoring probabilities across all sample groups are between 33% and 37% (found by simulating 100,000 censoring and survival time random variables each), for $\lambda = 0.5$, these probabilities range from 39.5% to 41.5%, and for $\lambda = 2/3$, they even reach values between 48.5% and 49%; resulting in only 5 to 7 uncensored observations per group. On the other hand, not to restrict the time horizon in inferential procedures about survival functions appears to slightly slow down the convergence of type I error probabilities to the nominal level as the sample size increases; see Dobler (2018) for similar findings in the context of confidence bands for unrestricted survival functions. However, the error probabilities recover for samples of double size (i.e. between 20 and 28) already: in the one-way design, these error rates drop to mainly 8.2% – 9.9%, and in all two-way tests, we even achieve rates of mainly 6.1% – 8%. If the sample sizes are tripled (i.e. between 30 and 42), most of the type I error probabilities are between 7% – 8% (one-way) or 5.2% – 6.9% (two-way). In case of the sample size factor $K = 5$, all results are only slightly liberal, and for $K = 10$ (i.e. sample sizes between 100 and 140), we see that the nominal level is well attained.

n	λ / K	1	2	3	5	10	n	λ / K	1	2	3	5	10
\mathbf{n}_1	λ_1	14.7	8.8	7.2	6.4	5.7	\mathbf{n}_1	λ_1	9.0	6.3	6.0	5.7	5.4
	λ_2	16.6	9.3	7.7	6.3	5.7		λ_2	9.0	6.7	6.0	5.6	4.6
	λ_3	19.7	11.0	8.6	6.6	5.8		λ_3	10.5	7.0	6.3	5.9	5.6
	λ_4	17.7	9.9	7.7	6.1	5.9		λ_4	10.1	6.7	6.1	5.7	5.7
	λ_5	17.4	9.5	7.8	6.7	6.3		λ_5	9.4	6.2	5.8	5.6	5.0
\mathbf{n}_2	λ_1	13.0	7.9	6.7	5.9	5.7	\mathbf{n}_2	λ_1	7.7	6.3	5.8	5.3	5.9
	λ_2	13.9	8.4	7.1	6.9	5.4		λ_2	8.1	6.3	6.0	6.0	5.3
	λ_3	16.5	9.1	7.8	6.2	5.8		λ_3	9.7	6.8	6.4	5.0	5.4
	λ_4	14.9	8.5	7.3	6.0	5.6		λ_4	8.2	6.3	6.2	5.9	5.4
	λ_5	14.6	9.0	6.8	6.3	5.6		λ_5	8.9	6.7	6.2	5.4	5.1
\mathbf{n}_3	λ_1	12.2	8.2	7.1	6.0	5.2	\mathbf{n}_3	λ_1	7.8	6.3	6.0	5.6	4.9
	λ_2	13.7	8.6	7.0	6.1	5.3		λ_2	8.5	6.2	5.5	5.3	5.0
	λ_3	17.7	9.3	7.6	6.8	5.9		λ_3	9.2	6.9	6.5	5.6	5.1
	λ_4	14.8	8.8	7.7	6.3	5.9		λ_4	8.4	6.1	6.1	5.8	4.5
	λ_5	14.1	8.6	7.2	6.3	5.9		λ_5	8.2	6.7	5.7	6.0	5.7

Table 1: Simulated type I error probabilities in a one-way layout (left) and in a two-way design for main effect A (right) with sample size factor K .

n	λ / K	1	2	3	5	10	n	λ / K	1	2	3	5	10
\mathbf{n}_1	λ_1	10.0	7.2	6.4	6.2	6.0	\mathbf{n}_1	λ_1	10.1	7.2	6.3	5.7	5.3
	λ_2	11.4	7.7	6.7	5.9	4.9		λ_2	11.2	7.2	6.2	5.9	5.1
	λ_3	13.4	8.0	6.9	5.9	5.8		λ_3	13.3	8.5	7.0	6.5	5.5
	λ_4	12.2	7.6	6.9	6.1	5.9		λ_4	11.6	7.8	6.6	6.1	5.3
	λ_5	12.1	7.5	6.7	5.9	5.6		λ_5	11.6	7.7	6.4	5.9	5.6
\mathbf{n}_2	λ_1	9.5	6.6	6.1	6.0	5.0	\mathbf{n}_2	λ_1	9.2	6.6	5.9	6.2	5.3
	λ_2	10.2	7.4	6.5	6.0	5.5		λ_2	9.8	6.9	6.6	5.4	5.7
	λ_3	11.6	7.8	6.6	5.6	5.7		λ_3	11.7	7.5	6.4	5.8	5.4
	λ_4	10.4	7.0	6.4	5.5	6.1		λ_4	9.8	6.8	6.4	5.2	5.0
	λ_5	10.2	7.1	6.2	5.9	5.4		λ_5	10.8	7.1	6.2	5.8	5.6
\mathbf{n}_3	λ_1	9.5	7.2	5.8	5.2	5.2	\mathbf{n}_3	λ_1	8.3	6.6	6.3	5.2	5.1
	λ_2	9.6	6.8	6.3	5.4	5.6		λ_2	9.6	6.9	5.9	5.8	5.7
	λ_3	11.6	7.4	6.9	6.2	5.6		λ_3	11.2	7.6	6.4	5.3	5.8
	λ_4	9.9	7.4	6.2	6.5	5.4		λ_4	10.4	6.9	5.8	5.4	4.7
	λ_5	9.7	7.2	6.4	5.7	5.0		λ_5	9.8	6.8	5.5	5.5	5.7

Table 2: Simulated type I error probabilities in a two-way design for main effect B (left) and for interaction effect AB (right) with sample size factor K .

5.2 Behaviour under shift alternatives

In addition to the simulations of the previous subsection, we also conducted a small power simulation of the above tests. For the alternative hypotheses, we considered a shift model: taking the same six basic survival and censoring functions as in the first set of simulations, we shift all survival and censoring times of the first sample group by $\delta \in \{0.1, 0.2, \dots, 1\}$. In this way, we maintain the same censoring rates as before and the distance to the null hypotheses is gradually increased: for growing $\delta > 0$, we obtain a growing relative effect $p_1 > 0.5$ (one-way) and $p_{11} > 0.5$ (two-way), respectively. For each of the above considered contract matrices, $\mathbf{C}_1, \mathbf{C}_{2,A}, \mathbf{C}_{2,B}, \mathbf{C}_{2,AB}$, we conducted one set of simulations with different unbalanced sample sizes and censoring rate combinations. For each set-up, we increased the sample sizes by the factors $K = 1, 3, 5$. The results are displayed in Figure 2.

We see that, even for the smallest sample sizes (between 10 and 14), the power of the two-way testing procedures increase to 0.5 or 0.6 as the shift parameter approaches 1. For larger samples sizes the theoretically proven consistency is apparent. In comparison, the one-way test has a much higher power: For the undersized case ($K = 1$) it already reaches a power of 0.8 while for moderate to larger sample sizes the power is almost 1 for shift parameters $\delta \geq 0.5$. In comparison to the two-way procedure its superior power is, however, partially paid at the price of its pronounced liberality; especially for small sample sizes.

All in all, the simulations confirm that all tests have a satisfactory power with increasing sample size and/or shift parameter while maintaining a reasonable control of the nominal level for sample sizes of 30 to 42 already.




Figure 2: Power functions for shift alternatives for different null hypotheses: in the one-way layout (sample sizes $\mathbf{n} = K \cdot \mathbf{n}_2$, censoring rates $\lambda = \lambda_5$), in the two-way layout for main effect A ($\mathbf{n} = K \cdot \mathbf{n}_3$, $\lambda = \lambda_4$), for main effect B ($\mathbf{n} = K \cdot \mathbf{n}_3$, $\lambda = \lambda_2$), and for the interaction effect ($\mathbf{n} = K \cdot \mathbf{n}_2$, $\lambda = \lambda_4$), $K = 1, 3, 5$. The nominal significance level is $\alpha = 5\%$ (- -).

6 Data example

We illustrate the developed theory on a dataset from a colon cancer study (Moertel et al., 1990). Considering the patients in *Stage C*, that is, there had been metastases to regional lymph nodes, the data consist of eligible 929 patients suffering from colon cancer. Survival (measured in days) was the primary endpoint of the study. We focus on the two factors ‘gender’ and ‘treatment’ (with three levels) to obtain a crossed 2×3 survival design which is in line with a setting from our simulation study. In particular, there were 315 patients in the observation group, 310 others were treated with levamisole, and 304 received levamisole, combined with fluorouracil. Levamisole was originally used as an anthelmintic drug and fluorouracil (5-FU) is a medicine to treat various types of cancer. The patients in the study had been randomized into one of these three treatment groups. Also, there were nearly as many women (445) as men (484) involved in the study. Figure 3 depicts the Kaplan-Meier estimates of the survival probabilities for each treatment \times sex subgroup. We refer to Moertel et al. (1990) for more details about the study. The dataset is freely accessible via the R command `data(colonCS)` after having loaded the package `condSURV` (Meira-Machado and Sestelo, 2016a,b).

The aim is now to investigate the presence of main or interaction effects of treatment and gender. As there are several ties in the data (roughly 16%; see Appendix C for details) and we do not want to impose specific distributional assumptions, we focus on the nonparametric concordance effects. To this end, we first have to choose a proper τ . From our retrospective view, the most reasonable choice is found by determining for each group the minimal observed censoring




Figure 3: Kaplan-Meier estimator for male and female subgroups, discriminated further according to treatment: obs = observation, lev = levamisole treatment, lev+fluo = combined levamisole and fluorouracil treatment. The end time in the plot is $\tau = \text{day } 2173$.

time that exceeds all observed survival times in that group. We call these censoring times “terminal times”. Then, τ is set to be the minimal terminal time. In doing so, the group with that minimum terminal time does not benefit nor does it suffer from having the earliest terminal time when compared to the other groups.

The first block in Table 3 shows the sample sizes of all subgroups. In the present data example, the minimal terminal time is $\tau = 2173$; see the second block of Table 3. In view of the sample sizes and the censoring rates given in the third block of Table 3, we compare the present dataset with the simulation set-ups in Section 5: a similarly strong censorship is obtained for λ_3 and comparable sample sizes $n \in [100, 140]$ for the choice $K = 10$. Thus, judging from the rightmost columns of Tables 1 and 2, we find it is safe to assume actual type I error probabilities of about 5.1% to 5.9% of the proposed nonparametric one- and two-way survival tests.

treatment	sample size		terminal time		censoring rate		effect size	
	male	female	male	female	male	female	male	female
observation	166	149	2800	2562	47.6	51.0	0.475	0.483
levamisole	177	133	2915	2173	47.5	52.6	0.459	0.501
levamisole plus fluorouracil	141	163	2726	2198	68.8	55.2	0.581	0.501

Table 3: For each subgroup: sample size, smallest censoring time (in days) exceeding the largest survival time, censoring rate (in %) after taking the minimum of each event time and $\tau = 2173$, and nonparametric concordance effects. Columns: sex, row: treatments.

We tested the data in one- and two-factorial set-ups and chose $\alpha = 5\%$ as the significance level. As in the simulation study, we used $B = 1,999$ bootstrap iterations for each test. For the tests in the two-factorial model, we considered the null hypotheses corresponding to no main treatment effect, no main effect in sex, and no interaction effect between both. The test results, by means of p-values, are shown in Table 4.

Null hypothesis	$H_0^p(\cdot)$	set-up	p-value
Equality of all effects	$H_0^p(\mathbf{C}_1)$	one-factorial	< 0.001
No main effect in sex	$H_0^p(\mathbf{C}_{2,A})$	two-factorial	0.331
No main effect in treatment	$H_0^p(\mathbf{C}_{2,B})$	two-factorial	< 0.001
No interaction effect	$H_0^p(\mathbf{C}_{2,AB})$	two-factorial	< 0.001

Table 4: p-values of different hypothesis tests for the analysis of the colonCS data-set.

We found a significant indication against the equality of all $d = 6$ groups (p-value < 0.001) but this difference between groups could not be inferred to result from a difference between the sexes (p-value = 0.331). However, we

found a significant treatment effect ($p\text{-value} < 0.001$) as well as a significant interaction effect between treatment and sex ($p\text{-value} < 0.001$). The p -values in Table 4 have not been adjusted for a type I error multiplicity but it is obvious that the results remain the same after an application of, say, the Bonferroni-Holm procedure.

Indeed, looking at the rightmost block of Table 3, we agree with the findings of the hypothesis tests: the gender effect seems to be cancelled out if the treatment groups are combined, but within the male gender there seems to be a big difference in the concordance effects ($p_{1i_2} \in [0.459, 0.581]$). Also, the interaction effect is apparent, as the female groups do not seem to strongly benefit from any treatment ($p_{2i_2} \in [0.483, 0.501]$). On the other hand, the male groups exhibit a worse than average survival fitness in the observation and the levamisole treatment group ($p_{11} = 0.475$, $p_{12} = 0.459$) but a much better than average survival fitness for the combination treatment ($p_{13} = 0.581$). Here the value $p_{13} = 0.581$ roughly means that a randomly generated observation from this specific group survives a randomly generated observation from the mean distribution of all groups with probability 58.1%. Taking another look at the Kaplan-Meier curves in Figure 3, we immediately see that our concordance effects and the test outcomes make sense. We clearly see that there is a big difference in the male survival probabilities (the combination treatment group is superior to the levamisole treatment group which is in turn superior to the observation group) but there is not much of a difference between the female groups' survival curves. Indeed, comparing the Kaplan-Meier curve of the pooled males' survival times with that of the pooled females' times, we graphically find no evident main gender effect. The plot of both Kaplan-Meier estimators is shown in Appendix C.

Finally, we relate our results to the original findings of Moertel et al. (1990) whose analyses involve the Cox proportional hazards model and logrank tests. The authors also detected that "Therapy with levamisole plus fluorouracil produced an unequivocal advantage over observation" and that levamisole alone did not produce a detectable effect. Furthermore, they concluded from an exploratory subset analysis that the "levamisole-fluorouracil treatment appeared to have the greatest advantage among male patients [...]". This is exactly what we confirm in our analysis based on the nonparametric two-factorial tests. However, Moertel et al. (1990) neither account for the present ties in the data (note that the Cox regression postulates continuous outcomes) nor did they clearly stress the rather weak effect of the levamisole-fluorouracil treatment for women. They just state that their "results show [...] striking contradictions to those of subset analyses reported in the NCCTG study, in which levamisole plus fluorouracil was found to be most effective in reducing the risk of recurrence among female patients [...]" among other subgroups of patients.

7 Discussion

We proposed novel nonparametric inference procedures for the analysis of factorial survival data that may be subject to independent random right-censoring. Critical values are obtained from a multiplier wild bootstrap approach leading to asymptotically valid tests and confidence regions for meaningful effect parameters. Thereby, the procedures do not require any multiplicative or additive hazard structure nor specific distributional survival and censoring assumptions. In particular, different group distributions are allowed and ties are accounted for accordingly. Moreover, different to the nonparametric survival procedures of Akritas and Brunner (1997) and Akritas (2011), our methods are not only driven towards hypothesis testing but also to uncertainty quantification of the underlying effect estimators. The latter can be used to comprehensibly describe and infer main and interaction effects in general nonparametric factorial survival designs with an arbitrary number of fixed factors. Together with a 1-1 connection with hazard ratios in proportional two-sample designs (Brückner and Brannath, 2017), this makes the new methods appealing for practical purposes.

To investigate their theoretical properties, we rigorously proved central limit theorems of the underlying statistics and consistency of the corresponding procedures. In addition, extensive simulations were conducted for one- and two-way designs to also assess their finite sample properties in terms of power and type- I -error control. In case of small sample sizes with less than 10 completely observed subjects per group, they revealed a liberal behaviour; especially for the one-way testing procedure. However, for moderate to larger sample sizes the asymptotic results kicked in and the stated theoretical results were recovered.

Finally, the methods were used to exemplify the analysis of survival data in a study about treatments for colon cancer patient within a two-factorial survival design. As severe ties were present in the data, classical hazard based methods were not directly applicable. In comparison, our newly proposed nonparametric methods provided a very decent alternative for the analysis of such factorial survival designs without postulating any strict assumptions.

To allow for a straightforward application, it is planned to implement the procedure into an easy to use R-package. In future research we will consider the case of stochastically ordered subgroups, for which a multiple testing algorithm could be developed with the aim to detect significantly different collections of all subgroups: subgroups with no significant differences in the nonparametric concordance effects may be combined to facilitate the interpretation of the outcomes and to ultimately serve for the development of different, more personalized medicines, one for each new subgroup combination. Moreover, extensions of the current methodology to ordered alternatives or factorial designs obtained via stratified sampling will be part of a practically useful consecutive testing procedure.

Acknowledgements

Markus Pauly likes to thank for the support from the German Research Foundation (Deutsche Forschungsgemeinschaft).

References

- M. G. Akritas. Nonparametric Models for ANOVA and ANCOVA Designs. In *International Encyclopedia of Statistical Science*, pages 964–968. Springer, 2011.
- M. G. Akritas and E. Brunner. Nonparametric Methods for Factorial Designs with Censored Data. *Journal of the American Statistical Association*, 92(438):568–576, 1997.
- P. K. Andersen, Ø. Borgan, R. D. Gill, and N. Keiding. *Statistical Models Based on Counting Processes*. Springer, New York, 1993.
- A. Bathke, M.-O. Kim, and M. Zhou. Combined multiple testing by censored empirical likelihood. *Journal of Statistical Planning and Inference*, 139(3):814–827, 2009.
- T. Bluhmki, D. Dobler, J. Beyersmann, and M. Pauly. The wild bootstrap for multivariate Nelson-Aalen estimators. *Lifetime Data Analysis*, early view, doi:10.1007/s10985-018-9423-x, 2018a.
- T. Bluhmki, C. Schmoor, D. Dobler, M. Pauly, J. Finke, M. Schumacher, and J. Beyersmann. A wild bootstrap approach for the Aalen-Johansen estimator. *Biometrics*, early view, doi:10.1111/biom.12861, 2018b.
- M. Brendel, A. Janssen, C.-D. Mayer, and M. Pauly. Weighted Logrank Permutation Tests for Randomly Right Censored Life Science Data. *Scandinavian Journal of Statistics*, 41(3):742–761, 2014.
- M. Brückner and W. Brannath. Sequential tests for non-proportional hazards data. *Lifetime data analysis*, 23(3):339–352, 2017.
- E. Brunner and U. Munzel. The Nonparametric Behrens-Fisher Problem: Asymptotic Theory and a Small-Sample Approximation. *Biometrical Journal*, 42(1):17–25, 2000.
- E. Brunner and M.L. Puri. Nonparametric methods in factorial designs. *Statistical papers*, 42(1):1–52, 2001.
- E. Brunner, H. Dette, and A. Munk. Box-Type Approximations in Nonparametric Factorial Designs. *Journal of the American Statistical Association*, 92(440):1494–1502, 1997.
- E. Brunner, F. Konietzschke, M. Pauly, and M.L. Puri. Rank-based procedures in factorial designs: hypotheses about non-parametric treatment effects. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)*, 79(5):1463–1485, 2017.
- E. Brunner, F. Konietzschke, A.C. Bathke, and M. Pauly. Ranks and pseudo-ranks – paradoxical results of rank tests. *arXiv preprint arXiv:1802.05650*, 2018.
- D. R. Cox. Regression Models and Life-Tables. *Journal of the Royal Statistical Society. Series B (Methodological)*, 34(2):187–220, 1972.
- D. Dobler. A discontinuity adjustment for subdistribution function confidence bands applied to right-censored competing risks data. *Electronic Journal of Statistics*, 11(2):3673–3702, 2017.
- D. Dobler. Bootstrapping the Kaplan-Meier Estimator on the Whole Line. *Annals of the Institute of Statistical Mathematics*, early view, 2018.
- D. Dobler and M. Pauly. Bootstrap-and permutation-based inference for the Mann-Whitney effect for right-censored and tied data. *TEST*, early view:1–20, 2017.
- D. Dobler, J. Beyersmann, and M. Pauly. Non-strange weird resampling for complex survival data. *Biometrika*, 104(3):699–711, 2017.
- D. Dobler, S. Friedrich, and M. Pauly. Nonparametric MANOVA in Mann-Whitney effects. *arXiv preprint arXiv:1712.06983*, 2018.
- S. Dutta and S. Datta. A rank-sum test for clustered data when the number of subjects in a group within a cluster is informative. *Biometrics*, 72(2), 2016.
- B. Efron. The two sample problem with censored data. In *Proceedings of the fifth Berkeley symposium on mathematical statistics and probability*, 4:831–853, 1967.

- W. Ehm, E. Mammen, and D. W. Müller. Power robustification of approximately linear tests. *Journal of the American Statistical Association*, 90(431):1025–1033, 1995.
- T. R. Fleming and D. P. Harrington. *Counting processes and survival analysis*. John Wiley & Sons, 2011.
- S. Friedrich, F. Konietschke, and M. Pauly. A wild bootstrap approach for nonparametric repeated measurements. *Computational Statistics & Data Analysis*, 113:38–52, 2017.
- X. Gao and M. Alvo. A unified nonparametric approach for unbalanced factorial designs. *Journal of the American Statistical Association*, 100(471):926–941, 2005.
- X. Gao and M. Alvo. Nonparametric multiple comparison procedures for unbalanced two-way layouts. *Journal of Statistical Planning and Inference*, 138(12):3674–3686, 2008.
- X. Gao, M. Alvo, J. Chen, and G. Li. Nonparametric multiple comparison procedures for unbalanced one-way factorial designs. *Journal of Statistical Planning and Inference*, 138(8):2574–2591, 2008.
- R. D. Gill and S. Johansen. A Survey of Product-Integration with a View Toward Application in Survival Analysis. *The Annals of Statistics*, 18(4):1501–1555, 1990.
- S. Green. Factorial designs with time to event endpoints. In *In: Crowley, J. and Hoering, A.: Handbook of Statistics in Clinical Oncology*, pages 199–209. CRC Press, 2012.
- S. Green, P.-Y. Liu, and J. O’Sullivan. Factorial design considerations. *Journal of Clinical Oncology*, 20(16):3424–3430, 2002.
- A. Janssen and G. Neuhaus. Two-sample rank tests for censored data with non-predictable weights. *Journal of statistical planning and inference*, 60(1):45–59, 1997.
- E. L. Kaplan and P. Meier. Nonparametric Estimation from Incomplete Observations. *Journal of the American Statistical Association*, 53(282):457–481, 1958.
- F. Konietschke, L.A. Hothorn, and volume=6 pages=738–759 year=2012 publisher=The Institute of Mathematical Statistics and the Bernoulli Society Brunner, E. journal=Electronic Journal of Statistics. Rank-based multiple test procedures and simultaneous confidence intervals.
- F. Konietschke, S. Friedrich, E. Brunner, and M. Pauly. *rankFD: Rank-Based Tests for General Factorial Designs*, 2016. URL <https://CRAN.R-project.org/package=rankFD>. R package v. 0.0.1.
- P.-Y. Liu and S. Dahlberg. Design and analysis of multiarm clinical trials with survival endpoints. *Controlled clinical trials*, 16(2):119–130, 1995.
- J. Lubsen and S.J. Pocock. Factorial trials in cardiology: Pros and cons, 1994.
- N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. *Cancer Chemother Rep*, 50:163–170, 1966.
- A. M. Mathai and S. B. Provost. *Quadratic forms in random variables: theory and applications*. Dekker, New York, 1992.
- L. Meira-Machado and M. Sestelo. condSURV: An R Package for the Estimation of the Conditional Survival Function for Ordered Multivariate Failure Time Data. *The R Journal*, 8(2):460–473, 2016a.
- L. Meira-Machado and M. Sestelo. *condSURV: Estimation of the Conditional Survival Function for Ordered Multivariate Failure Time Data*, 2016b. URL <https://CRAN.R-project.org/package=condSURV>. R package version 2.0.1.
- C. G. Moertel, T. R. Fleming, J. S. Macdonald, D. G. Haller, J. A. Laurie, P. J. Goodman, J. S. Ungerleider, W. A. Emerson, D. C. Tormey, J. H. Glick, M. H. Veeder, and J. A. Mailliard. Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma. *New England Journal of Medicine*, 322(6):352–358, 1990.
- R Development Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria, 2010–2015. URL <http://www.R-project.org>.
- T. H. Scheike and M.-J. Zhang. An additive–multiplicative cox–aalen regression model. *Scandinavian Journal of Statistics*, 29(1):75–88, 2002.
- T. H. Scheike and M.-J. Zhang. Extensions and applications of the cox-aalen survival model. *Biometrics*, 59(4):1036–1045, 2003.

- M. Umlauf, F. Konietzschke, and M. Pauly. Rank permutation approaches for nonparametric factorial designs. *Brit J Math Stat Psy*, 70:368–390, 2017a.
- M. Umlauf, M. Placzek, F. Konietzschke, and M. Pauly. Wild bootstrapping rank-based procedures: Multiple testing in nonparametric split-plot designs. *arXiv preprint arXiv:1710.04532*, 2017b.
- A. W. van der Vaart and J. A. Wellner. *Weak Convergence and Empirical Processes*. Springer, New York, 1996.
- S. Yang and R. Prentice. Improved logrank-type tests for survival data using adaptive weights. *Biometrics*, 66(1):30–38, 2010.

Appendix

A Proofs

Proof of Lemma 1

The proof of this lemma is based on an extension of the results of Dobler and Pauly (2017). In that article it is shown that the functional $\tilde{\phi} : (BV[0, \tau])^2 \rightarrow \mathbb{R}$, $(f, g) \mapsto -\int_0^\tau f^\pm(u)dg(u)$ is Hadamard-differentiable in functions of bounded variation; see the proof of their Theorem 1 in the supplement to that article for more details. Hence, a similar result transfers to the functional ϕ in the present article because ϕ is simply a multivariate aggregation of functionals of the same type as $\tilde{\phi}$.

For the sake of completeness, we point out that the $((i-1)d+j)$ th entry of continuous and linear Hadamard-derivative of ϕ at \mathbf{S} is given by

$$(d\phi_{\mathbf{S}} \cdot \mathbf{h})_{i,j} = \int h_j^\pm dS_i - \int h_i^\pm dS_j, \quad \mathbf{h} = (h_1, \dots, h_d)' \in (D[0, \tau])^d,$$

if $h_1(0) = \dots = h_d(0) = 0$ which indeed is the case in the present application.

The other fundamental result that we require is the convergence of all normalized Kaplan-Meier estimators in distribution. It is well-known that $\sqrt{n_i}(\hat{S}_i - S_i) \xrightarrow{d} U_i$ on the Skorokhod space $D[0, \tau]$ as $n_i \rightarrow \infty$ in the present situation of independent right-censoring. Hence, due to the independence of all sample groups, it also follows that $\text{diag}(n_1, \dots, n_d) \cdot (\hat{\mathbf{S}} - \mathbf{S}) \xrightarrow{d} \mathbf{U}$ on $(D[0, \tau])^d$ as $\min(n_1, \dots, n_d) \rightarrow \infty$.

Thus, after having added the multiplicative term $\frac{\sqrt{n_i}}{\sqrt{n_i}}$ in each component $i = 1, \dots, d$, it follows by means of the functional delta-method (cf. Theorem 3.9.4 in van der Vaart and Wellner, 1996) that $\sqrt{N}(\phi(\hat{\mathbf{S}}) - \phi(\mathbf{S}))$ converges in distribution as asserted. \square

Proof of Theorem 1

This convergence result follows immediately from Lemma 1 in combination with the continuous mapping theorem. \square

Proof of Lemma 2

It is well-known that each Kaplan-Meier estimator \hat{S}_i and also each covariance function estimator $\hat{\Gamma}_i$ is uniformly consistent on $[0, \tau]$ for S_i and on $[0, \tau]^2$ for Γ_i , respectively, $i = 1, \dots, d$. Note here that due to the assumption $P(T_{i1} > \tau) > 0$ for all groups i the cumulative hazard functions are bounded on the interval of interest: $\Lambda_i(\tau) < \infty$.

Since $\hat{\mathbf{V}}_N$ is a continuous functional of these estimators, it follows from the continuous mapping theorem that the matrix $\hat{\mathbf{V}}_N$ is consistent for \mathbf{V} . Likewise, we conclude that the estimator $\text{tr}(\mathbf{T}\hat{\mathbf{V}}_N)$ is consistent for the trace $\text{tr}(\mathbf{T}\mathbf{V})$ due to continuity of the trace and linear maps. \square

Proof of Theorem 2

Again, the result essentially follows from the continuous mapping theorem as $\mathbf{p} \mapsto \mathbf{p}'\mathbf{T}\mathbf{p}$ is a continuous map. Thus, taking Lemma 2 into account, an application of Slutsky's lemma reveals that

$$F_N(\mathbf{C}) \xrightarrow{d} \chi$$

under $H_0^p(\mathbf{C})$ as $N \rightarrow \infty$.

To show that χ has unit expectation, we note that the trace in the denominator of $F_N(\mathbf{C})$ accounts for the asymptotic expectation of the quadratic form term: the expectation of a quadratic form $\mathbf{X}'\mathbf{A}\mathbf{X}$ for a random vector \mathbf{X} with mean

$\boldsymbol{\mu} = E(\mathbf{X})$ and covariance matrix $\boldsymbol{\Sigma} = \text{cov}(\mathbf{X})$ equals $E(\mathbf{X}'\mathbf{A}\mathbf{X}) = \text{tr}(\mathbf{A}\boldsymbol{\Sigma}) + \boldsymbol{\mu}'\mathbf{A}\boldsymbol{\mu}$; cf. Corollary 3.2b.1 in Mathai and Provost (1992). In our situation, where $\mathbf{A} = \mathbf{T}$ and $\mathbf{T}\mathbf{p} = \mathbf{0}$ under $H_0^p(\mathbf{C})$, the asymptotic expectation of $N\hat{\mathbf{p}}'\mathbf{T}\hat{\mathbf{p}}$ under H_0^p thus simplifies to $\text{tr}(\mathbf{T}\mathbf{V})$.

On the other hand, under the alternative hypothesis $H_a^p(\mathbf{C})$, we have that

$$F_N(\mathbf{T}) = \frac{N}{\text{tr}(\mathbf{T}\widehat{\mathbf{V}}_N)} \hat{\mathbf{p}}'\mathbf{T}\hat{\mathbf{p}} = \frac{N}{\text{tr}(\mathbf{T}\widehat{\mathbf{V}}_N)} (\hat{\mathbf{p}} - \mathbf{p})'\mathbf{T}(\hat{\mathbf{p}} - \mathbf{p}) + \frac{N}{\text{tr}(\mathbf{T}\widehat{\mathbf{V}}_N)} (2\hat{\mathbf{p}} - \mathbf{p})'\mathbf{T}\mathbf{p}.$$

The first term on the right-hand side converges in distribution to χ as $N \rightarrow \infty$. Of the second term, $(2\hat{\mathbf{p}} - \mathbf{p})'\mathbf{T}\mathbf{p}$ converges to the positive number $\mathbf{p}'\mathbf{T}\mathbf{p}$. Thus, an application of Slutsky's lemma yields that $F_N(\mathbf{T}) \xrightarrow{p} \infty$ as $\min \mathbf{n} \rightarrow \infty$. \square

Proof of Theorem 3

This conditional central limit theorem holds because for each wild bootstrapped Kaplan-Meier estimator a conditional central limit theorem holds separately; cf. Dobler (2017) who suggested a wild bootstrap resampling technique for independently right-censored competing risks and survival data in the presence of ties. They are combined with the help of the continuous mapping theorem and also with the consistency of the wild bootstrapped covariance estimators which were shown in that same paper. Hence, the continuous mapping theorem implies that the conditional distribution of $F_N^*(\mathbf{T})$ given the data converges weakly in probability to the distribution of χ . \square

B Asymptotic Covariance Matrix \mathbf{V} of $\sqrt{N}(\hat{\mathbf{p}} - \mathbf{p})$

The covariance matrix \mathbf{V} in Theorem 1 has the compact form

$$\begin{aligned} \mathbf{V} &= \frac{1}{d^2} \sum_{j=1}^d \frac{1}{\lambda_j} \int \int \Gamma_j^{\pm\pm} d\mathbf{S}d\mathbf{S}' + \int \int \text{diag}\left(\left(\frac{1}{\lambda_i} \Gamma_i^{\pm\pm}\right)_{i=1}^d\right) d\bar{S}d\bar{S} \\ &\quad - \frac{1}{d} \int \int \left(\frac{1}{\lambda_i} \Gamma_i^{\pm\pm}\right)_{i=1}^d d\bar{S}d\mathbf{S}' - \left(\frac{1}{d} \int \int \left(\frac{1}{\lambda_i} \Gamma_i^{\pm\pm}\right)_{i=1}^d d\bar{S}d\mathbf{S}'\right)' \\ &= \frac{1}{d^2} \int \int \mathbf{1}'_d \text{diag}(\boldsymbol{\lambda})^{-1} \boldsymbol{\Gamma}^{\pm\pm} d\mathbf{S}d\mathbf{S}' + \text{diag}(\boldsymbol{\lambda})^{-1} \int \int \text{diag}(\boldsymbol{\Gamma}^{\pm\pm}) d\bar{S}d\bar{S} \\ &\quad - \frac{1}{d} \int \int \text{diag}(\boldsymbol{\lambda})^{-1} \boldsymbol{\Gamma}^{\pm\pm} d\bar{S}d\mathbf{S}' - \left(\frac{1}{d} \int \int \text{diag}(\boldsymbol{\lambda})^{-1} \boldsymbol{\Gamma}^{\pm\pm} d\bar{S}d\mathbf{S}'\right)', \end{aligned}$$

where $\boldsymbol{\Gamma} = (\Gamma_i)_{i=1,\dots,d}$ is the vectorial aggregation of asymptotic covariance functions of all Kaplan-Meier estimators.

C Additional Information on the Data Analysis

As stated in Section 6 of the paper there are severe ties present in the dataset. The explicit numbers of ties are presented in Table 5 below. They show that 130 different observations occurred at least twice in the data set. In particular, only 781 different realizations are encountered among all 929 individuals leading to a ties rate of roughly $148/929 \approx 16\%$.

Observations that appear			
once	twice	three times	four times
651	115	12	3

Table 5: Number of ties in the data before we truncated at $\tau = 2173$ days

After choosing the truncation time $\tau = 2173$ days as described in the paper, the numbers of ties further increase as illustrated in Table 6. This leads to a ties rate of approximately $439/929 \approx 47\%$ in the final data analysis.

Observations that appear				
once	twice	three times	four times	361 times
421	59	7	2	1

Table 6: Number of ties in the data after we truncated at $\tau = 2173$ days

Finally, we present in Figure 4 the Kaplan-Meier curves with respect to gender, thus after a combination of all three male subgroups and all three female subgroups. Even though the test for the main effect in gender was not detected to be significant in the set-up with six subgroups, we found that gender became highly significant if the two-sample problem is

considered (p-value < 0.001). Indeed, in Figure 4 the survival times of male patients appear to be slightly stochastically larger than those of the females. We thus see that the tests further gain in power when different subgroups are combined as the involved sample sizes increase a lot. Of course, one should be careful with this new result because combining subgroups may not always make sense. In this case, especially in view of the significant interaction effect between treatment and gender, it could be reasonable to treat women differently than men.




Figure 4: Kaplan-Meier curves for male (black) and female patients (red).